Directorio

To join this study, patients must have a new diagnosis of cervical cancer confirmed by a lab test. The cancer can be one of these types: squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma. The cancer must be locally advanced, which means it has grown but has not spread far. It can be stage III or stage IVA. Patients cannot have had their whole uterus removed for cervical cancer, but if part of the uterus was removed for another reason, they can still join. They cannot plan to have their uterus removed as part of their treatment. The cancer cannot have spread to certain lymph nodes high in the body. Patients must not have had surgery, radiation, or medicine for cervical cancer before. They also cannot have had immunotherapy or radiation to the pelvis for any reason. Patients must be 18 or older.

We are doing this study to find out if an experimental drug called navtemadlin (the study drug) is a safe and effective option for people with myelofibrosis (MF). We want to know how well it works when it is combined with ruxolitinib for people who did not get the desired results from ruxolitinib on its own.

People in this study will be placed into one of three groups. They will receive either L19IL2, L19TNF, or both L19IL2 and L19TNF. These treatments are given once a week for up to 4 weeks, or until the person’s tumors are gone.

L19IL2/L19TNF

We are doing this study to find the most effective, safe dose of an experimental drug called CLN-049 (the study drug) for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).